Disease Landscape and Forecast Insights

Obesity is a significant public health concern. Although inexpensive phentermine is commonly prescribed for weight management, newer therapies like glucagon-like peptide-1 (GLP-1) receptor agonists…

Among bipolar disorder (BPD) patients, depressive episodes are typically more common than manic or mixed episodes; symptoms of bipolar depression include fatigue, insomnia, suicidal ideation, and…

Asthma is a common chronic airway disease that affects children and adults. The asthma therapy market in China consists of many well-established agents, including inhaled agents (GSK’s Advair /…

In 2023, Lundbeck / Otsuka’s Rexulti became the first FDA-approved drug to treat agitation associated with Alzheimer’s disease (AD). Other novel agents are now emerging as potential treatments…

The treatment of neuropathic pain involves the use of drugs from several classes, including antidepressants, antiepileptic drugs, local anesthetics, dual-acting opioid analgesics, and opioid…

Hyperkalemia is a potentially life-threatening condition characterized by a serum potassium concentration that exceeds 5.5 mEq/L. Despite various guidelines, a universally accepted consensus on the…

In the United States, osteoarthritic pain affects about 32 million people; an aging population and the increasing prevalence of obesity are predicted to fuel additional growth. Several treatment…

Metformin is the most heavily prescribed type 2 diabetes (T2D) drug and dominates the early lines of therapy before disease progression requires insulin replacement. The emergence of more-effective…

Muscular dystrophy (MD) is a spectrum of genetic disorders characterized by muscle weakness that, in severe forms, can lead to loss of ambulation and early mortality. Treatments are needed that can…

Heart failure with reduced ejection fraction (HFrEF) has a well-established drug treatment with a wealth of supporting evidence from clinical trials. ACE inhibitors, or ARBs, beta blockers, and…

Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases, and even though understanding of the disease’s pathophysiology has…

Chronic heart failure (CHF) is a long-term condition primarily managed by angiotensin-converting enzyme (ACE) inhibitors, oral beta blockers, or oral diuretics. The addition of a second- or third-…